"Ignota Labs has harvested more assets for its drug candidate rehabilitation scheme, snapping up Kronos Bio’s clinical pipeline months after a series of setbacks drove the biotech off public markets. U.K.-based Ignota has created software for identifying the root causes of drug safety problems. The goal is to improve safety without compromising efficacy. Ignota is applying the system to drug candidates that were derailed by safety setbacks"
"Ignota has identified Kronos’ clinical pipeline as a good fit for the model. The deal covers CDK9 inhibitor istisociclib and two SYK inhibitors, entospletinib and lanraplenib. Kronos stopped work on the assets for a range of reasons over the past few years, triggering waves of layoffs and culminating in its acceptance of a buyout bid from Concentra Biosciences."
Read more:
‘Ignota buys Kronos' pipeline, igniting 2nd chance salvo to rescue shelved programs,’ can be read in full at Fierce Biotech.
Published: 06 October 2025 by Fierce Biotech.
Picture: Chalabala/iStock/Getty Images Plus
